Physician profile
Stephen L Schmidt
NPI 1790784593
$5,392.12
in general payments reported to CMS, 2019-2025
37 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $400 · 2021: $856 · 2022: $913 · 2023: $1,145 · 2024: $1,098 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,070.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,400.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $966.97 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Abbott Laboratories | $405.43 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $314.66 | 2020-2025 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $281.64 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.94 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $203.14 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.62 | 2022-2025 | |
| Lilly USA, LLC | $155.86 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $142.16 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $122.23 | 2020-2024 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $113.44 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $109.54 | 2022-2025 | |
| Astellas Pharma US INC | $78.05 | 2021-2024 | Veozah |
| Corcept Therapeutics | $70.34 | 2025 | Korlym |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $60.55 | 2021-2023 | Eliquis |
| Allergan, INC. | $56.60 | 2019-2020 | |
| Dexcom, INC. | $53.43 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.03 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $50.04 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $37.32 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Corium, LLC | $34.75 | 2023-2024 | Azstarys |
| Antares Pharma, INC. | $29.68 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Globus Medical, INC. | $26.25 | 2025 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $25.99 | 2021-2022 | |
| Echosens North America, INC. | $24.92 | 2023 | Fibroscan |
| Neos Therapeutics, Lp | $22.54 | 2020 | |
| Xeris Pharmaceuticals, INC. | $21.41 | 2025 | Keveyis |
| Phathom Pharmaceuticals, INC. | $20.57 | 2025 | Voquezna |
| Mylan Specialty L.P. | $18.17 | 2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.75 | 2022 | |
| Stryker Corporation | $16.58 | 2025 | Clottriever Bold Catheter |
| Sanofi Pasteur INC. | $14.56 | 2021 | |
| Esperion Therapeutics, INC. | $13.98 | 2024 | Nexletol |
| Boston Scientific Corporation | $13.10 | 2021 | |
| Exact Sciences Corporation | $12.75 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.